The main clinical purpose of this combination hormonal contraceptive is to provide continuous hormonal contraception, serving as a foundational method of birth control for women who elect to use it for prevention of pregnancy. The primary purpose is relevant in clinical practice.

The medication is commonly used to help manage symptoms related to reproductive health and systemic imbalance, including menstrual irregularities, severe menstrual cramping (Dysmenorrhea), and excessive monthly blood loss (Menorrhagia). It is also relevant for easing symptoms like visible acne in susceptible women and is considered relevant for easing symptoms linked to functional ovarian cysts.

“The primary therapeutic application is to provide continuous support for the prevention of conception, which is commonly associated with the secondary benefit of managing distressing menstrual symptoms.”

This approach may assist with maintaining a sense of stability and predictability in the monthly cycle. By moderating pronounced symptoms, the medication contributes to easing the overall symptom load and supports improved day-to-day comfort during symptomatic periods.

Quick Fact: Symptomatic Relief Gracial is applied for symptomatic relief in patients experiencing severe menstrual cramping (Dysmenorrhea) and excessive monthly blood loss.

Regulatory References

1. NIH DailyMed Drug Label for Desogestrel and Ethinyl Estradiol

Who Can and Cannot Use Gracial?

The eligibility to use Gracial, a combined hormonal contraceptive containing desogestrel and ethinyl estradiol, is strictly defined by regulatory authorities based on a patient's medical history and current health status. It is primarily allowed for post-menarcheal women seeking pregnancy prevention.

Contraindicated Populations (Must Not Use)

Use is contraindicated in women with a history of thromboembolic disorders (e.g., Deep Vein Thrombosis or stroke) or known thrombophilic conditions. It is also absolutely prohibited for women over 35 years of age who smoke. Further contraindications include known or suspected breast cancer or other estrogen-dependent neoplasia, active liver disease or hepatic tumors, and severe uncontrolled hypertension.

Conditional and Age-Related Use

• Pregnancy & Lactation: Use is contraindicated during known or suspected pregnancy. It is not recommended during breastfeeding as the hormones may pass into breast milk.
• Age Groups: The medicine is not indicated for use in elderly women, and use in children who have not yet started menstruating is not recommended.
• Surgical Risk: Use must be discontinued at least four weeks before major surgery associated with increased blood clot risk and for two weeks following prolonged immobilization.

Interactions with other medicines and products

Official regulatory information for Gracial (Desogestrel and Ethinyl Estradiol) establishes clear restrictions based on documented pharmacokinetic alterations and specific combination prohibitions.

Interaction Scope

Official Interaction Statements:

• Co-administration with regimens containing ombitasvir/paritaprevir/ritonavir is formally contraindicated due to the documented potential for significant ALT elevations.
• The use of Gracial is contraindicated in females over 35 years of age who smoke cigarettes due to a highly increased risk of serious cardiovascular events.
• Enzyme-inducing drugs (e.g., Rifampicin, certain anticonvulsants) cause increased clearance of the contraceptive steroids, leading to decreased systemic exposure and the potential for loss of efficacy.
• Ethinyl Estradiol is documented to inhibit the clearance of co-administered drugs like caffeine and corticosteroids, resulting in their increased plasma concentrations.

This profile establishes regulatory-mandated constraints on co-administration with specific medicinal products, certain drug classes, and documented substances.

Gracial contains ethinylestradiol and desogestrel, synthetic steroid hormones that function as agonists at their respective intracellular nuclear receptors, the Estrogen Receptor (ER) and the Progesterone Receptor (PR).

The primary molecular action is the suppression of gonadotropins, specifically Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), via negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. Ethinylestradiol and the active metabolite of desogestrel, etonogestrel, act on the hypothalamus to decrease the pulse frequency of Gonadotropin-Releasing Hormone (GnRH). Etonogestrel, a potent PR agonist, directly inhibits the secretion of FSH and LH from the anterior pituitary, preventing the follicular development necessary for ovulation and inhibiting the mid-cycle LH surge. This leads to the system-level physiological consequence of anovulation.

Secondary mechanisms include etonogestrel's local interaction in the lower genital tract, which modifies the cervical mucus to increase viscosity and reduce sperm transit. Furthermore, the compounds induce alterations in the endometrium, reducing its thickness and receptivity. The estrogen component, ethinylestradiol, also upregulates the synthesis of Sex Hormone-Binding Globulin (SHBG) in the liver, which alters the circulating free fraction of other steroids.

Gracial is a biphasic combined oral contraceptive, meaning it contains two different combinations of the active hormonal ingredients ethinylestradiol and desogestrel across its 22-day dosing cycle.

Standard Dosing Regimen

The Gracial blister pack contains 22 active tablets and should be taken as a continuous 28-day regimen. The tablets must be taken daily, at approximately the same time each day, in the order indicated by the arrows and the days of the week on the blister strip. Swallow the tablet whole with a small amount of water if needed.

After the 22 active tablets are completed, a 6-day hormone-free interval follows, during which a withdrawal bleed usually occurs. Start a new pack on the 29th day, regardless of whether the bleeding has stopped. Consistent, correct use is essential to maintain maximum contraceptive effectiveness.

Starting the First Pack

The optimal time to begin Gracial is on the first day of your natural menstrual period (Day 1 start). If started between Day 2 and Day 5 of your cycle, you must use a non-hormonal barrier method (e.g., condoms) for the first 7 consecutive days of taking the active tablets as a precautionary measure against pregnancy.

Gracial: Recent Clinical Evidence

This section summarizes the research evidence evaluating the drug's scope of investigation and the outcomes examined in clinical studies. Gracial is a combination oral contraceptive containing ethinyl estradiol and desogestrel.

I. Core Efficacy Studies

Clinical trials have consistently focused on the high contraceptive effectiveness of the combination. Early multicenter studies confirmed the high contraceptive reliability and cycle control. Research trials primarily focused on short-term periods of study in healthy participants.

• Method Effectiveness: Studies evaluating the monophasic formulation (containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol) have reported high contraceptive efficacy when used correctly.
• Non-Contraceptive Outcomes: Research has explored the combination's effects on certain conditions. In studies involving women with hirsutism, treatment was associated with a significant decrease in free testosterone and 3-alpha-androstanediol glucuronide levels, with improvements noted in clinical scores.

II. Safety and Patient Considerations

Research has examined the safety profile of the drug's use over different durations in adults and its metabolic characteristics.

• Tolerability: The formulation has generally been reported to be well tolerated in studies involving first-time users, with bleeding irregularities being among the most frequently reported adverse events. Long-term studies monitored the frequency of adverse events over periods up to six months.
• Pharmacokinetics: Studies assessed pharmacokinetics to understand drug absorption and elimination. Research compared plasma concentration levels under different administration conditions (e.g., in a fasted state versus following a meal) to characterize the drug's metabolism.
• Specific Populations: Evidence remains limited regarding the drug's use in patients under the age of 18. Ongoing studies continue to evaluate the safety and appropriate dosage range for this population, while data collection also addresses use in individuals with underlying conditions.

Key Studies & References

1. Desogestrel/Ethinylestradiol, tablets (Summary of Product Characteristics - National Authorisation)

Common questions about Gracial (FAQ)

Q: What should I do if I forget to take a pill?

Official regulatory documents provide specific, detailed instructions for managing a missed dose, which can vary based on the number of pills forgotten and when in the cycle the miss occurred. The general principle often involves taking the missed pill as soon as remembered and may include the temporary use of a non-hormonal barrier method for a specified number of days.

Q: Is Gracial used for anything other than birth control?

The formal indication for Gracial is the prevention of pregnancy (contraception). However, studies and official information indicate that the combination of hormones may also have effects on conditions such as hirsutism, which is the excessive growth of dark or coarse hair.

Q: Can I use Gracial if I'm currently taking an antibiotic?

Official product information cautions that some medicines, including certain antibiotics like Rifampicin, are known as 'enzyme-inducing drugs.' These may cause the contraceptive steroids to clear from the body faster, potentially reducing Gracial's effectiveness. When co-administered with such a drug, official product information often advises that additional non-hormonal contraception may be necessary during and after that treatment period.

Q: What is the difference between the blue and white tablets?

Gracial is officially classified as a biphasic combined oral contraceptive. This means that the active tablets are designed to contain two different dosage levels of the hormones ethinylestradiol and desogestrel across the 22-day dosing cycle. The different colors correspond to these two distinct hormone combinations.

Q: How long does it take for Gracial to start working for contraception?

According to official product information, contraceptive protection can begin immediately if the medication is started on the very first day of your natural menstrual period. The official label indicates that if the medication is started at another time in the cycle, the temporary use of a non-hormonal barrier method is generally recommended for the first seven consecutive days of active tablet use.

Storage and Disposal Requirements for Gracial

Gracial (desogestrel / ethinyl estradiol) must be stored strictly according to regulatory labeling to maintain its stability.

Storage Conditions

Gracial tablets must be kept at a temperature below 30 C. To protect the active ingredients from degradation, the medicine must be stored in its original container and outer carton to shield it from light and moisture. This is necessary to ensure the product remains stable through its labeled shelf-life. The medicine must also be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Gracial must be disposed of safely and responsibly. Regulatory guidance dictates that the product must not be thrown into household waste or flushed down the toilet (via wastewater). Instead, disposal must be carried out in accordance with local pharmaceutical waste requirements.